国内地区 :
欢迎光临，！登录 | 注册
中文 英语
0 购物车
400-968-6088
产品中心
生化试剂
抗生素 维生素 动植物激素 酸&盐&胺 糖及衍生物 脂质＆脂肪酸衍生物 核酸&核苷酸及衍生物 氨基酸&蛋白质 酶&辅酶 表面活性剂&去垢剂&螯合剂 氘代试剂 稳定同位素 反应底物 常规生化试剂 通用缓冲液
蛋白与免疫
重组蛋白 蛋白提取/定量 免疫佐剂 细胞全蛋白 抗原 蛋白电泳 抗体标记试剂盒 其它实验试剂
多肽
封闭肽 化妆品肽 目录肽 定制肽
抗体
一抗 二抗 内参抗体 细菌抗体 标签抗体 RNA抗体 植物抗体 小分子抗体 病毒抗体
ELISA
人 小鼠 大鼠 通用 其他种属 未包被试剂盒 抗体对 Elisa辅助试剂
流式分析
流式辅助试剂
分子生物学
核酸提取/纯化 PCR/qPCR 分子克隆相关酶 核酸电泳 重组克隆表达 质粒 分子杂交 分子生物学辅助试剂 MBI原装
细胞生物学
细胞系（株） 细胞器提取试剂盒 细胞培养基Kit 细胞培养与消化 细胞分离液 细胞生长因子 细胞检测 鲎试剂 植物培养
小分子化合物
迷你化合物Kit 抑制剂＆拮抗剂＆激动剂 疾病造模剂 明星产品 Peptides 化合物库 PROTAC/蛋白降解靶向嵌合分子 同位素标记物 氨基酸及其衍生物 Anti-infection/抗感染 糖类及其衍生物 维生素及其衍生物 助溶剂&增溶剂 染料&探针 反应底物&理化检测 实验常用溶液
生化试剂盒
氮代谢系列 脂肪酸代谢系列 糖类代谢系列 其他生化系列 氧化还原系列 蛋白及酶类系列 能量代谢系列
染色试剂
染色原料 荧光染色液 HE染色液 组织染色液 植物染色液 酶类染色液 特殊细胞染色液 胞内组分染色液 微生物染色液 辅助试剂 组织切片制备试剂
分析标准品
分析对照品 紫外分光标准品 可溯源标准品 对照药材 仪器检定标液 单标溶液 混标套装 液相色谱用试剂盒 分析辅助试剂 质控标样/基质标物 代销产品
微生物培养
菌株 培养基基础 培养基原料 培养基添加剂 发酵专用产品 酵母缺陷型培养基 其他微生物培养基 微生物辅助试剂 OXOID原装
层析介质
预装柱 填料
磁珠
纯化磁珠 免疫沉淀 纳米抗体磁珠 基础磁珠
仪器、耗材
基础耗材 培养耗材 PCR&分子生物学耗材 WB&免疫耗材 药敏纸片 病理制片耗材 安全防护耗材 其他耗材 层析用耗材 实验仪器
纳米材料
石墨/石墨烯 类石墨烯 碳纳米材料 无机纳米材料 分子筛 金属纳米材料 其它纳米材料
化学合成
分子砌块 PEG衍生物 金属材料

活动
> 顺铂
顺铂

CAS:No.15663-27-1

英文名称:Cisplatin

分子式:Cl2H6N2Pt

分子量:300.05

储存条件:Powder: 2-8℃，2 years

纯度:HPLC≥98%

   说明书下载
顺铂
满3999赠露营车
货号：
IC0440
品牌：
Solarbio
SKU 北京总部 北京海淀 武汉 广州
IC0440-200mg 咨询 咨询 咨询 咨询
IC0440-500mg 咨询 咨询 咨询 咨询
IC0440-100mg 咨询 咨询 咨询 咨询
IC0440-20mg 咨询 咨询 咨询 咨询
IC0440-5mg 咨询 咨询 咨询 咨询
IC0440-10mg 咨询 咨询 咨询 咨询
IC0440-50mg 咨询 咨询 咨询 咨询
IC0440-1g 咨询 咨询 咨询 咨询
数量：
-
+
加入购物车
立即购买
产品简介 相关产品 相关论文 COA 技术问答

使用本产品的应用案例（仅供参考）：

In Vivo

Mice（Four- to 6-week-old male BALB/C nude mice；5 mg/kg cisplatin，intraperitoneally administered，every week for 2 weeks）

Four- to 6-week-old male BALB/C nude mice were subcutaneously injected with 1 × 106 cells near the extremities of four limbs. When the mice developed palpable tumors, the mice were intraperitoneally administered with cisplatin (5 mg/kg; Solarbio Company) every week for 2 weeks. The size of the tumors was measured once every 3 days, six times in a row.  All animals were sacrificed 25 days after inoculation, and the tumors were collected.The tumor tissues were photographed, and immunohistochemistry was performed.

来源文献：Gong L, Xiao M, He D, Hu Y, Zhu Y, Xiang L, Bao Y, Liu X, Zeng Q, Liu J, Zhou M, Zhou Y, Cheng Y, Zhang Y, Deng L, Zhu R, Lan H, Cao K. WDHD1 Leads to Cisplatin Resistance by Promoting MAPRE2 Ubiquitination in Lung Adenocarcinoma.  Front Oncol. 2020 Apr 24;10:461.  doi: 10.3389/fonc.2020.00461.  PMID: 32426268;  PMCID: PMC7212426.



Mice (Heterozygous DDX39A knockout mice (C57BL/6N), after overnight incubation, the cells were exposed to various concentrations of cisplatin for a duration of 48 hours)

Cisplatin-resistant HCT116 and SKOV3 cells, denoted HCT116/DDP and SKOV3/DDP, respectively, were generated by subjecting the corresponding parental cells to prolonged treatment with incrementally increasing concentrations of cisplatin.

To assess cellular drug sensitivity, a CCK-8 assay was used. Initially, cells were seeded into 96-well plates at a density of 4000 cells per well. After overnight incubation, the cells were exposed to various concentrations of cisplatin for a duration of 48 hours. Subsequently, 10 mLof CCK-8 solution was added to each well, followed by a 2-hour incubation.

来源文献：Xu Z, Nie C, Liao J, Ma Y, Zhou XA, Li X, Li S, Lin H, Luo Y, Cheng K, Mao Z, Zhang L, Pan Y, Chen Y, Wang W, Wang J. DDX39A resolves replication fork-associated RNA-DNA hybrids to balance fork protection and cleavage for genomic stability maintenance. Mol Cell. 2024 Dec 13:S1097-2765(24)00954-7. doi: 10.1016/j.molcel.2024.11.029. Epub ahead of print. PMID: 39706185.


In Vitro

Cell（HCT116 and SKOV3 cells，various concentrations of cisplatin for a duration of 48 hours）

To assess cellular drug sensitivity, a CCK-8 assay was used. Initially, cells were seeded into 96-well plates at a density of 4000 cells per well. After overnight incubation, the cells were exposed to various concentrations of cisplatin for a duration of 48 hours. Subsequently, 10 mLof CCK-8 solution was added to each well, followed by a 2-hour incubation. The absorbance was measured using a microplate reader at a wavelength of 450 nm. Semilogarithmic dose-response curves for cisplatin were generated using GraphPad Prism.

文献来源：Xu Z, Nie C, Liao J, Ma Y, Zhou XA, Li X, Li S, Lin H, Luo Y, Cheng K, Mao Z, Zhang L, Pan Y, Chen Y, Wang W, Wang J. DDX39A resolves replication fork-associated RNA-DNA hybrids to balance fork protection and cleavage for genomic stability maintenance. Mol Cell. 2025 Feb 6;85(3):490-505.e11. doi: 10.1016/j.molcel.2024.11.029. Epub 2024 Dec 19. PMID: 39706185.


Cell（Platinum-sensitive humanovarian papillary serous adenocarcinoma cell line OV-90 (ATCC#CRL11732)，10, 20, 40, 80, 100, and 120mM to generate chemoresistant OV-90/DDP cell lines）

Cells were subjected to treatment with escalating concentrations of cisplatin (DDP, IC0440,Beijing Solarbio Science and Technology Co.), specifically 10, 20, 40,80, 100, and 120mM to generate chemoresistant OV-90/DDP cell lines. Cisplatin at a concentration of 10 mM was introduced when the cells reached the exponential phase, with subsequent concentrations administered at the same phase until a final concentration of 120 mM was achieved. The culture conditions of the cell lines were preserved in accordance with those of the original OV-90 cell line during the entire culture period. Cells from each concentration phase were cultured with platinum drugs for a minimum of two weeks, with medium changes occurring every two days. Cisplatin-resistantsubclones were generated by intermittently exposing cells to 2 mM cisplatin while maintaining aconcentration of 100 mM to sustain chemoresistant clones. The concentration indicates the threshold that cells can endure without compromising reproductive viability. The resistant cell line OV-90/DDP was established after 12 months of induction. The cell line tested negative for mycoplasma contamination.

来源文献：Ren F, Pang X, Jin F, Luan N, Guo H, Zhu L. Integration of scRNA-seq and bulk RNA-seq to reveal the association and potential molecular mechanisms of metabolic reprogramming regulated by lactylation and chemotherapy resistance in ovarian cancer. Front Immunol. 2025 Feb 28;16:1513806. doi: 10.3389/fimmu.2025.1513806. PMID: 40093000; PMCID: PMC11907005.


备注：
以上数据均来自公开文献, Solarbio暂未进行独立验证, 仅供参考。
These protocols are for reference only. Solarbio does not independently validate these methods.

实验图
暂无详情
Liu H, et al. Breast Cancer Res. 2023 Apr 17;25(1):43.
Pan Y, et al. Microsyst Nanoeng. 2020 Mar 9;6:23.
Gong L, et al. Front Oncol. 2020 Apr 24;10:461.
Pan Y, et al. Biosens Bioelectron. 2019 Apr 1;130:344-351.
Xu Z et al. Mol Cell. 2024 Dec 13:S1097-2765(24)00954-7. doi: 10.1016/j.molcel.2024.11.029.
Xu Z, et al.Mol Cell. 2025 Feb 6;85(3):490-505.e11. doi: 10.1016/j.molcel.2024.11.029.
Ren F,et al.Front Immunol. 2025 Feb 28;16:1513806. doi: 10.3389/fimmu.2025.1513806.
Ren F,et al.Front Immunol. 2025 Feb 28;16:1513806. doi: 10.3389/fimmu.2025.1513806.
注意：
1.本产品仅供科研使用。请勿用于医药、临床诊断或治疗，食品及化妆品等用途。请勿存放于普通住宅区。
2.为了您的安全和健康，请穿好实验服并佩戴一次性手套和口罩操作。
3.实验结果可由多种因素影响，相关处理只限于产品本身，不涉及其他赔偿。
为科研服务、为生命尽责
联系方式
地址: 北京市通州区马驹桥联东U谷85号
客服电话: 400-968-6088
技术邮箱: service@solarbio.com
采购邮箱: purchase@solarbio.com
销售邮箱: sales-china@solarbio.com
订购指南
服务保证
资料下载
Copyright © 2004-2022 北京索莱宝科技有限公司. 版权所有.
 京ICP备12051307号-7 
京公网安备 11011202000391号